logo
About
R&D
Pipeline
Investors
News
Contact
For Patients
Primary Sclerosing Cholangitis
Nonalcoholic Steatohepatitis (NASH)
(NASH) דלקת כבד על רקע שומני
Investor Relations
Investor Relations
Overview
News & Events
News
Events
Presentations
Contact IR
Email Alerts
Financials & Filings
SEC Filings
Annual Reports
Quarterly Results
Stock
Stock Quote & Chart
Historical Stock Price
Analyst Coverage
Corporate Governance
Board Committees
Board of Directors
Leadership
Documents
News
Events
Presentations
Contact IR
Email Alerts
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Email Alerts
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
May 24, 2023
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update
May 11, 2023
Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference
April 26, 2023
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
April 19, 2023
Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update
April 12, 2023
Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023
March 29, 2023
Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update
March 17, 2023
Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 06, 2023
Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis
February 21, 2023
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
January 03, 2023
Load More
Loading...